Search Results - "Macon, R."

Non‐Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: A longitudinal analysis of the National Cancer Data Base from 1998 to 2011 by Al‐Hamadani, Mohammed, Habermann, Thomas M., Cerhan, James R., Macon, William R., Maurer, Matthew J., Go, Ronald S.

“…The World Health Organization classification of non‐Hodgkin lymphoma (NHL) was introduced in 2001. However, its incorporation into clinical practice is not…”
Get full text

Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412 by Nowakowski, Grzegorz S, Hong, Fangxin, Scott, David W, Macon, William R, King, Rebecca L, Habermann, Thomas M, Wagner-Johnston, Nina, Casulo, Carla, Wade, James L, Nagargoje, Gauri G, Reynolds, C M, Cohen, Jonathon B, Khan, Nadia, Amengual, Jennifer E, Richards, Kristy L, Little, R F, Leonard, John P, Friedberg, Jonathan W, Kostakoglu, Lale, Kahl, Brad S, Witzig, Thomas E

“…Lenalidomide combined with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) (R2CHOP) in untreated diffuse large B-cell…”
Get full text

Higher response to lenalidomide in relapsed/refractory diffuse large B‐cell lymphoma in nongerminal center B‐cell–like than in germinal center B‐cell–like phenotype by Hernandez‐Ilizaliturri, Francisco J., Deeb, George, Zinzani, Pier L., Pileri, Stefano A., Malik, Farhana, Macon, William R., Goy, Andre, Witzig, Thomas E., Czuczman, Myron S.

“…BACKGROUND: There is a need to develop novel therapies for relapsed/refractory diffuse large B‐cell lymphoma (DLBCL) and to identify biomarkers predictive for…”
Get full text

Rates and Outcomes of Follicular Lymphoma Transformation in the Immunochemotherapy Era: A Report From the University of Iowa/Mayo Clinic Specialized Program of Research Excellence Molecular Epidemiology Resource by LINK, Brian K, MAURER, Matthew J, COLGAN, Joseph P, WITZIG, Thomas E, HABERMANN, Thomas M, CERHAN, James R, NOWAKOWSKI, Grzegorz S, ANSELL, Stephen M, MACON, William R, SYRBU, Sergei I, SLAGER, Susan L, THOMPSON, Carrie A, INWARDS, David J, JOHNSTON, Patrick B

“…Purpose This study sought to characterize transformation incidence and outcome for patients with follicular lymphoma (FL) in a prospective observational series…”
Get full text

Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma by Thompson, Carrie A, Ghesquieres, Herve, Maurer, Matthew J, Cerhan, James R, Biron, Pierre, Ansell, Stephen M, Chassagne-Clément, Catherine, Inwards, David J, Gargi, Thérèse, Johnston, Patrick B, Nicolas-Virelizier, Emmanuelle, Macon, William R, Peix, Marie, Micallef, Ivana N, Sebban, Catherine, Nowakowski, Grzegorz S, Porrata, Luis F, Weiner, George J, Witzig, Thomas E, Habermann, Thomas M, Link, Brian K

“…We examined the utility of post-therapy surveillance imaging in a large, prospectively enrolled cohort of patients with diffuse large B-cell lymphoma (DLBCL)…”
Get full text

Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements by McPhail, Ellen D, Maurer, Matthew J, Macon, William R, Feldman, Andrew L, Kurtin, Paul J, Ketterling, Rhett P, Vaidya, Rakhee, Cerhan, James R, Ansell, Stephen M, Porrata, Luis F, Nowakowski, Grzegorz S, Witzig, Thomas E, Habermann, Thomas M

“…High-grade B-cell lymphomas with and and/or rearrangements (double-/triple-hit lymphoma) have an aggressive clinical course. We investigated the prognostic…”
Get full text

Expression of p63 protein in anaplastic large cell lymphoma: Implications for genetic subtyping by Wang, Xueju, Boddicker, Rebecca L, Dasari, Surendra, Sidhu, Jagmohan S, Kadin, Marshall E, Macon, William R, Ansell, Stephen M, Ketterling, Rhett P, Rech, Karen L, Feldman, Andrew L

“…Anaplastic large cell lymphomas (ALCLs) are CD30-positive T-cell non-Hodgkin lymphomas that bear chromosomal rearrangements of the TP53 homologue, TP63 , in a…”
Get full text

Vitamin D Insufficiency and Prognosis in Non-Hodgkin's Lymphoma by DRAKE, Matthew T, MAURER, Matthew J, JOHNSTON, Patrick B, SINGH, Ravinder J, ALLMER, Cristine, SLAGER, Susan L, WEINER, George J, WITZIG, Thomas E, CERHAN, James R, LINK, Brian K, HABERMANN, Thomas M, ANSELL, Stephen M, MICALLEF, Ivana N, KELLY, Jennifer L, MACON, William R, NOWAKOWSKI, Grzegorz S, INWARDS, David J

“…Vitamin D insufficiency is common in the United States, with low levels linked in some studies to higher cancer incidence, including non-Hodgkin's lymphoma…”
Get full text

Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas by Feldman, A L, Law, M, Remstein, E D, Macon, W R, Erickson, L A, Grogg, K L, Kurtin, P J, Dogan, A

“…Oncogenes involved in recurrent chromosomal translocations serve as diagnostic markers and therapeutic targets in hematopoietic tumors. In contrast to myeloid…”
Get full text

Specificity of IRF4 translocations for primary cutaneous anaplastic large cell lymphoma: a multicenter study of 204 skin biopsies by Wada, David A, Law, Mark E, Hsi, Eric D, DiCaudo, David J, Ma, Linglei, Lim, Megan S, Souza, Aieska de, Comfere, Nneka I, Weenig, Roger H, Macon, William R, Erickson, Lori A, Özsan, Nazan, Ansell, Stephen M, Dogan, Ahmet, Feldman, Andrew L

“…Current pathologic criteria cannot reliably distinguish cutaneous anaplastic large cell lymphoma from other CD30-positive T-cell lymphoproliferative disorders…”
Get full text

Role of systemic high‐dose methotrexate and combined approaches in the management of vitreoretinal lymphoma: A single center experience 1990‐2018 by Castellino, Alessia, Pulido, Jose S., Johnston, Patrick B., Ristow, Kay M., Nora Bennani, N., Inwards, David J., Macon, William R., Micallef, Ivana N. M., King, Rebecca L., Salomao, Diva R., Witzig, Thomas E., Habermann, Thomas M., Nowakowski, Grzegorz S.

“…Vitreoretinal lymphoma (VRL) management remains a challenge. We present 72 patients with VRL, diagnosed at Mayo Clinic between 1990‐2018. Three nondiffuse…”
Get full text

Detection of extranodal and spleen involvement by FDG‐PET imaging predicts adverse survival in untreated follicular lymphoma by St‐Pierre, Frédérique, Broski, Stephen M., LaPlant, Betsy R., Ristow, Kay, Maurer, Matthew J., Macon, William R., Habermann, Thomas M., Ansell, Stephen M., Thompson, Carrie A., Micallef, Ivana N. M., Nowakowski, Grzegorz S., Witzig, Thomas E.

“…Predicting early clinical failure in patients with untreated follicular lymphoma (FL) is important but difficult. This study aimed to determine the incidence…”
Get full text

Bowel perforation in intestinal lymphoma: incidence and clinical features by Vaidya, R., Habermann, T.M., Donohue, J.H., Ristow, K.M., Maurer, M.J., Macon, W.R., Colgan, J.P., Inwards, D.J., Ansell, S.M., Porrata, L.F., Micallef, I.N., Johnston, P.B., Markovic, S.N., Thompson, C.A., Nowakowski, G.S., Witzig, T.E.

“…Perforation is a serious life-threatening complication of lymphomas involving the gastrointestinal (GI) tract. Although some perforations occur as the initial…”
Get full text

Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study by Nowakowski, G S, LaPlant, B, Habermann, T M, Rivera, C E, Macon, W R, Inwards, D J, Micallef, I N, Johnston, P B, Porrata, L F, Ansell, S M, Klebig, R R, Reeder, C B, Witzig, T E

“…Lenalidomide was shown to have significant single-agent activity in relapsed aggressive non-Hodgkin's lymphoma (NHL). We conducted a phase I trial to establish…”
Get full text

Prognostic Analysis for Survival in Adult Solid Organ Transplant Recipients With Post-Transplantation Lymphoproliferative Disorders by GHOBNAL, Irene M, HABERMANN, Thomas M, STEGALL, Mark D, MCGREGOR, Christopher G, MAURER, Matthew J, GEYER, Susan M, RISTOW, Kay M, LARSON, Timothy S, WALKER, Randall C, ANSELL, Stephen M, MACON, William R, GORES, Gregory G

“…The objective of this study was to determine prognostic factors for overall survival in patients with post-transplantation lymphoproliferative disorders…”
Get full text

Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphoma by Bennani, N. Nora, LaPlant, Betsy R., Ansell, Stephen M., Habermann, Thomas. M., Inwards, David J., Micallef, Ivana N., Johnston, Patrick B., Porrata, Luis F., Colgan, Joseph P., Markovic, Svetomir N., Nowakowski, Grzegorz S., Macon, William R., Reeder, Craig B., Mikhael, Joseph R., Northfelt, Donald W., Ghobrial, Irene M., Witzig, Thomas E.

“…Relapsed indolent lymphoma often becomes refractory to standard chemoimmunotherapy and requires new therapeutic strategies. Targeting the PI3K/mTOR pathway in…”
Get full text

Overexpression of Syk tyrosine kinase in peripheral T-cell lymphomas by Feldman, A L, Sun, D X, Law, M E, Novak, A J, Attygalle, A D, Thorland, E C, Fink, S R, Vrana, J A, Caron, B L, Morice, W G, Remstein, E D, Grogg, K L, Kurtin, P J, Macon, W R, Dogan, A

“…Peripheral T-cell lymphomas (PTCLs) are fatal in the majority of patients and novel treatments, such as protein tyrosine kinase (PTK) inhibition, are needed…”
Get full text

Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials by Maurer, Matthew J, Ghesquières, Hervé, Link, Brian K, Jais, Jean-Philippe, Habermann, Thomas M, Thompson, Carrie A, Haioun, Corinne, Allmer, Cristine, Johnston, Patrick B, Delarue, Richard, Micallef, Ivana N, Peyrade, Frederic, Inwards, David J, Ketterer, Nicolas, Farooq, Umar, Fitoussi, Olivier, Macon, William R, Molina, Thierry J, Syrbu, Sergei, Feldman, Andrew L, Slager, Susan L, Weiner, George J, Ansell, Stephen M, Cerhan, James R, Salles, Gilles A, Witzig, Thomas E, Tilly, Hervé, Nowakowski, Grzegorz S

“…Purpose Selection bias in clinical trials has consequences for scientific validity and applicability of study results to the general population. There is…”
Get full text

Is the Time Right to Start Using Digital Pathology and Artificial Intelligence for the Diagnosis of Lymphoma? by Salama, Mohamed E., Macon, William R., Pantanowitz, Liron

Get full text

Patterns of therapy initiation during the first decade for patients with follicular lymphoma who were observed at diagnosis in the rituximab era by Arushi Khurana, Mwangi, Raphael, Ansell, Stephen M., Habermann, Thomas M., Cerhan, James R., Strouse, Christopher, Link, Brian K., Wang, Yucai, King, Rebecca L., Macon, William R., Villasboas, J. C., Witzig, Thomas E., Maurer, Matthew J., Nowakowski, Grzegorz S.

“…Immediate treatment for asymptomatic, low-tumor burden follicular lymphoma (FL) has not shown an overall survival benefit over “watch and wait” (W/W) strategy…”
Get full text